CASE STUDY PRA‘s Strategies Impress Client Tight Timelines, Last-minute Changes — No ProblemPRA’s Strategies Impress Client Tight Timelines, Last-minute Changes — No Problem Regions North America Latin America Western Europe Central Europe Eastern Europe Middle East North Africa Asia Pacific STUDY DESCRIPTION A randomized, double-blind, placebo-controlled study of the safety and tolerability of Study Drug and its effects on biomarkers in subjects with coronary artery disease PRA was awarded a global Phase II safety and tolerability study of a drug with a novel action for the treatment of coronary artery disease. The study, which involved more than 130 sites and 700 patients, encountered many challenges due to last-minute design and operational changes and tight timelines.

Join for free to read